WO2012049697A1 - Préparation pour traitement antiride basée sur des micro-patchs de caféine et des polysaccarides beta-glucanes - Google Patents

Préparation pour traitement antiride basée sur des micro-patchs de caféine et des polysaccarides beta-glucanes Download PDF

Info

Publication number
WO2012049697A1
WO2012049697A1 PCT/IT2011/000345 IT2011000345W WO2012049697A1 WO 2012049697 A1 WO2012049697 A1 WO 2012049697A1 IT 2011000345 W IT2011000345 W IT 2011000345W WO 2012049697 A1 WO2012049697 A1 WO 2012049697A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
topical use
beta
caffeine
glucan
Prior art date
Application number
PCT/IT2011/000345
Other languages
English (en)
Inventor
Carmine Antropoli
Original Assignee
Carmine Antropoli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carmine Antropoli filed Critical Carmine Antropoli
Publication of WO2012049697A1 publication Critical patent/WO2012049697A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin

Definitions

  • the present invention relates to the cosmeceutical sector and more in particular to the topical use of a preparation based on an association of active 5 ingredients for antiwrinkle treatment comprising caffeine micro-patches and beta-glucan polysaccharides.
  • the local use on dry and clean skin of a preparation based upon an association of caffeine micro-patches and beta-glucan 10 polysaccharides enables excellent results to be achieved in terms of effectiveness in the treatment of face wrinkles of a degree varying from slight-moderate to serious.
  • a further embodiment envisages associating to said 15 active ingredients, i.e., caffeine micro-patches and beta-glucan polysaccharides, at least one other eudermal and emollient ingredient that is not photosensitive, chosen in the group constituted by: hyaluronic acid, almond oil, isopropyl myristate, 20 native collagen, vitamin E ⁇ tocopheryl acetate) .
  • cosmetic is meant that sector of cosmetics and pharmaceuticals that regards the 25 treatment not of a condition but of the personal image.
  • Wrinkles unfortunately represent the most visible and recognizable sign of ageing. They present as more or less accentuated furrows in the skin and are the result of biochemical and histological alterations.
  • Wrinkles can form in various regions of the body, preferring the skin of the face, which is more exposed to pollutant environmental agents and is continuously stressed by the action of the underlying muscles.
  • nifedipine that acts at a muscular level, blocking the calcium channels, which perform a key role in the contraction of the sarcoma.
  • said cream is prepared with the addition of oils and emollients such as macadamia oil, palmitic acid, retinic acid, etc.
  • oils and emollients such as macadamia oil, palmitic acid, retinic acid, etc.
  • the use of the cream in question is, however, limited to applications carried out in the evening in so far as nifedipine is photosensitive and, if it is subjected to solar radiation, its structure is altered and loses its capacity for modulating the excessive stimulation of the mimetic muscles.
  • the subject of the present invention is a day cream for the treatment of face wrinkles of a degree varying from slight-moderate to serious, which is based upon the association of a caffeine micro-patch and of beta-glucan polysaccharides, in combination with one or more other active ingredients chosen in the group constituted by: collagen, hyaluronic acid (sodium hyaluronate) , almond oil, isopropyl myristate, and vitamin E.
  • the caffeine micro-patch is a recent biotechnological acquisition and is constituted by a reticular structure that makes it possible to carry into the deeper layers of the epidermis a very high concentration of caffeine and to release it gradually thus prolonging the effectiveness thereof over time.
  • the micro-patch performs an "enveloping effect" behaving as an invisible ⁇ remodelling sheath' that renders the skin smoother and more compact in a short time.
  • the caffeine micro-patch used in the product forming the subject of the invention is produced by BASF and has the following composition: caffeine 10-25 wt%; salicilic acid 10-25 wt%; butylene glycol 5-10 wt%; propylene glycol alginate 0.1-1 wt%; Senegal acacia 0.1-1 wt%; methyl parabenzene 0.1-1 wt%; water 10-25 wt%.
  • the percentage of caffeine micro- patches in the product forming the subject of the present invention is 1 wt%.
  • Beta-glucans are linear polysaccharides of D- glucose monomers bound by glycoside bonds of the beta type. They constitute a vast and heterogeneous group of molecules that can vary a great deal as regards molecular weight, solubility, viscosity, and three- dimensional configuration, and consequently as regards modalities of action and biological activity. Many are the properties recognized for beta-glucans. Some forms of beta-glucans are used in the food sector as thickening agents and as integrators of soluble fibres. They are widely used both in cosmetic products and in dermatological products.
  • fibroblasts which are important in tissue regeneration. They moreover possess important non-specific immunostimulating properties in the cicatrizing process.
  • beta-glucans deriving from yeast and medicinal fungi are notable for their capacity to modulate the immune system.
  • a particular type of beta-glucan is used, which was chosen by the applicants precisely on account of its specific properties, which are such as to bestow a given technical effect upon the composition forming the subject of the present invention: it is a biologically active polysaccharide deriving from beta- (1,3)/ (1,6) glucan isolated, and not extracted, from the edible fungus Pleurotus ostreatus, marketed by the company Pleuran under the tradename PleraSAN CH .
  • the patented process technology with which PleraSAN CH ® is obtained enables production .of a beta-glucan, of natural derivation, in the form of an aqueous suspension, without any residual impurities.
  • the beta-glucan of the preparation used in the antiwrinkle treatment according to the invention is completely natural and already soluble without requiring carboxymethylation .
  • this type of chemical modification which is commonly performed on similar beta-glucans in order to render them water- soluble in any case alters the degree of purity and, in the ultimate analysis, the biological effectiveness.
  • the beta-glucan used in the composition according to the invention is consequently without proteins and lipid residues. This improves the activity of the active molecule and reduces the risks of allergic reactions.
  • PleraSAN CH ® produced by the company Pleuran, is present in the formulation for the antiwrinkle treatment according to the invention in a percentage of 0.2 wt%, and is in turn constituted by beta- (1, 3) / (1, 6) glucan in an amount of 2 wt%, sodium benzoate in an amount of 0.09 wt%, chloroacetamide in an amount of 0.21 wt%, and water in an amount of 97.7 wt%.
  • Sweet-almond oil [Prunus amygdalus dulcis) , which can be contained in the formulation in the range of from 5% to 10%, presents markedly emollient and elasticizing properties, aiding and promoting skin regeneration. It is moreover known to be involved in the prevention and reduction of stretch marks.
  • Isopropyl myristate which can be contained in the formulation in the range of from 8 to 15%, has eudermal, emollient properties and functions as carrier of the various active ingredients, facilitating passage thereof through the cutaneous barrier.
  • Hyaluronic acid or sodium hyaluronate, which can be contained in the formulation in the range of from 1% to 0.5%, is a fundamental component of the derma. Thanks to its properties, it bestows upon the skin elasticity and softness, has the capacity of penetrating the layers of the epidermis and of acting from inside the skin to "fill" and relax the wrinkles.
  • hyaluronic acid protects the organism from viruses and bacteria, increases the plasticity of the tissues, and guarantees optimal hydration of the skin. It moreover presents cicatrizing and anti-inflammatory properties.
  • Native collagen which can be contained in the formulation in the range of from 1 to 3%, is used in cosmetics as filling material for correcting imperfections, scars, and wrinkles.
  • Vitamin E or tocopheryl acetate, which can be contained in the formulation in the range of from 0.5% to 2%, is used in many cosmetic products thanks to its hydrating power and its ease of absorption. Its capacity for softening and protecting the skin against the dehydrating effect of sun, wind, and pollutant agents, renders it particularly useful in preparations for sun creams and after-sun creams.
  • vitamin E is used as antioxidant in order to protect from the damage caused by the excess of free radicals.
  • a mixture of benzyl alcohol, dehydroacetic acid, and water (respectively in the amounts of 75 to 94 wt%, 5 to 10 wt%, and 1 to 5 wt%), produced by BASF and marketed under the tradename Isocide Bas ® , is used as preserving agent and is present in a percentage of 0.8 wt% in the final formulation of the product according to the invention.
  • the overall duration of the study was 74 days
  • the study was a double-blind study conducted on volunteers .
  • the evaluation of the treatment was conducted at 0 and at 15, 30, and 60 days.
  • UV radiation and chemical substances, smoking history, prior treatments with creams/substances/antiwrinkle interventions , presence nervous tics) ;
  • Step I of the experiment the starting sample of 40 subjects was divided into two subgroups of 20 persons each; the two subgroups were comparable in reference to the distribution of gender, age, and state of the skin prior to treatment.
  • the first subgroup was treated with the antiwrinkle cream forming the subject of the invention.
  • the second subgroup was treated with a hydrating cream with a basis of emollient oils and caffeine micro-patches .
  • the cosmetic target expected of the cream handed to the subjects and the modalities of application of the product were illustrated to all of them; in particular, in order to favour a smoothing effect on the wrinkles, a morning application was prescribed, after careful cleansing of the skin with products having a natural pH, exerting a slight circular massaging followed by slight tapping of the skin to favour complete absorption of the product.
  • the envisaged duration of the treatment was two months.
  • test examiners were not cognisant of whether the subjects belonged to one subgroup or the other.
  • all the subjects underwent a clinical test that envisaged the evaluation of some skin parameters such as: pH, level of hydration achieved, depth and type of wrinkle; in elderly patients (who had wrinkles of severe degree) also an evaluation was performed on the face cast.
  • subgroup 1 treated with the cream forming the subject of the invention, showed an objective improvement of the wrinkles of 20% (self-perception of improvement of 25%) ;
  • subgroup 2 treated with hydrating cream + caffeine micro-patch, presented an objective improvement of the wrinkles of 10% ( self-perception of improvement of 15%) .
  • subgroup 1 showed an objective improvement of the wrinkles of 55% and of hydration of 60% (self- perception of improvement of the wrinkles of 50% and of hydration of 55%); subgroup 2 presented, instead, an objective improvement of the wrinkles of 25% and of hydration of 35% (self-perception of improvement of the wrinkles of 25% and of hydration of 40%) .
  • subgroup 1 presented an objective improvement of the wrinkles of 85% and of hydration of 95% (self- perception of improvement of the wrinkles of 70% and of hydration of 80%) ;
  • subgroup 2 showed, instead, an objective improvement of the wrinkles of 45% and of hydration of 55% (self-perception of improvement of the wrinkles of 45% and of hydration of 50%) .
  • subgroup 1 treated with the cream forming the subject of the invention
  • the subjects of subgroup 1 were invited not to apply any skin product for at least the next two weeks in order to obtain an evaluation of the possible long-duration effects and benefits.
  • the tolerability of the product proved to be 100%.
  • the cream proved effective in 85% of the subjects, obtaining persistent and appreciable results in these subjects even after two weeks from suspension of the treatment in 87.5% of the patients.
  • the skin hydration is clearly greater after application of the cream forming the subject of the invention for 30 days (70% as against 40%, respectively) .
  • the association of the two compounds determines a reduction of the wrinkles at rest in 85% of the subjects (as against 45% in the subjects treated just with caffeine micro- patches) .
  • the cream forming the subject of the invention has proven effective as a treatment that at the same time has a hydrating effect and the effect of improving the skin based upon the association of caffeine micro-patches and beta-glucan in the presence of other markedly eudermal and emollient ingredients (soluble collagen, sodium hyaluronate, vitamin E, vitamin A) , specifically devised for arousing the resources of the skin, stimulating the natural capacity of the skin for-hydration and rendering the skin smoother .
  • markedly eudermal and emollient ingredients soluble collagen, sodium hyaluronate, vitamin E, vitamin A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une crème basée sur l'association de deux principaux principes actifs, à savoir des micro-patchs de caféine et des polysaccharides béta-glucanes, ayant un effet de synergie sur le traitement antiride si on le compare à l'action de chaque principe actif. En particulier, ladite crème est capable de déterminer une réelle réduction des rides en association avec d'autres principes actifs à propriétés eudermiques et émollientes, qui agissent avec une forte synergie et action coadjuvante.
PCT/IT2011/000345 2010-10-12 2011-10-11 Préparation pour traitement antiride basée sur des micro-patchs de caféine et des polysaccarides beta-glucanes WO2012049697A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000540 2010-10-12
ITRM2010A000540A IT1405781B1 (it) 2010-10-12 2010-10-12 Uso di un preparato basato su micro-patch di caffeina e polisaccaridi di betaglucano in trattamenti antirughe.

Publications (1)

Publication Number Publication Date
WO2012049697A1 true WO2012049697A1 (fr) 2012-04-19

Family

ID=43738303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2011/000345 WO2012049697A1 (fr) 2010-10-12 2011-10-11 Préparation pour traitement antiride basée sur des micro-patchs de caféine et des polysaccarides beta-glucanes

Country Status (2)

Country Link
IT (1) IT1405781B1 (fr)
WO (1) WO2012049697A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189703A3 (fr) * 2012-06-20 2014-06-26 Beiersdorf Ag Préparation cosmétique et dermatologique contenant une ou plusieurs substances modulant le gène / la protéine pour le récepteur endo180
JP2016196421A (ja) * 2015-04-03 2016-11-24 株式会社Adeka 化粧料組成物
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11998575B2 (en) 2020-11-20 2024-06-04 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266064A1 (en) * 2004-05-29 2005-12-01 Mccarthy Kathryn J Cosmetic compositions and methods
WO2008153662A2 (fr) * 2007-05-22 2008-12-18 Access Business Group International Llc Compositions de raffermissement et de lifting de la peau et procédés d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266064A1 (en) * 2004-05-29 2005-12-01 Mccarthy Kathryn J Cosmetic compositions and methods
WO2008153662A2 (fr) * 2007-05-22 2008-12-18 Access Business Group International Llc Compositions de raffermissement et de lifting de la peau et procédés d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [Online] Mintel; "Cell Cream Slenderness Care", XP002637640, Database accession no. 1117042 *
DATABASE GNPD [online] Mintel; July 2007 (2007-07-01), "Intensive Rebuilding Instant Line Filler", XP002637639, Database accession no. 733863 *
DATABASE GNPD [online] Mintel; October 2008 (2008-10-01), "Super Line Prevetor Xtreme Lifting Concentrate", XP002637638, Database accession no. 993023 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189703A3 (fr) * 2012-06-20 2014-06-26 Beiersdorf Ag Préparation cosmétique et dermatologique contenant une ou plusieurs substances modulant le gène / la protéine pour le récepteur endo180
EP2982365A3 (fr) * 2012-06-20 2016-05-18 Beiersdorf AG Preparation cosmetique et dermatologique contenant une ou plusieurs substances modulant la proteine/gene pour le recepteur endo180
JP2016196421A (ja) * 2015-04-03 2016-11-24 株式会社Adeka 化粧料組成物
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11633451B2 (en) 2016-03-31 2023-04-25 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11998575B2 (en) 2020-11-20 2024-06-04 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient

Also Published As

Publication number Publication date
IT1405781B1 (it) 2014-01-24
ITRM20100540A1 (it) 2012-04-13

Similar Documents

Publication Publication Date Title
KR101772139B1 (ko) 피부 케어 제형
TWI246428B (en) Skin conditioner
US20070048245A1 (en) Cosmetic composition to accelerate repair of functional wrinkles
CN110664644B (zh) 一种含叶酸的护肤组合物、精华及其制备方法
CA2662581A1 (fr) Composition cosmetique pour le traitement de la peau et procedes correspondants
WO2012049697A1 (fr) Préparation pour traitement antiride basée sur des micro-patchs de caféine et des polysaccarides beta-glucanes
CN113576975A (zh) 一种易吸收的抗衰老组合物及其制备方法和应用
CN114796024B (zh) 用于皮肤屏障修复的仿生皮脂组合物及其制备方法和应用
KR20180015963A (ko) 보습 유지력이 우수한 피부 각질제거용 화장료 조성물
CN111631965A (zh) 一种植物来源的具有清洁和卸妆功能的面膜
US20180360712A1 (en) Cosmetic composition and use thereof
AU2002324634B2 (en) Method of skin exfoliation
AU2002324634A1 (en) Method of skin exfoliation
US7306810B1 (en) Skin cream
EP3470116A1 (fr) Composition cosmétique pour la peau et utilisation d'une composition cosmétique
WO2016033899A1 (fr) Composition antipelliculaire permettant de rétablir l'équilibre du cuir chevelu
WO2013188774A2 (fr) Formulations de soin de la peau comprenant des complexes octapeptidiques et procédés pour les fabriquer
JP7289833B2 (ja) 植物ゾウゲ抽出物（ファイテレファス属種（Ｐｈｙｔｅｌｅｐｈａｓ ｓｐ．））の化粧的使用
CN109350576B (zh) 具有补水保湿功效的组合物及其应用、化妆水及其制备方法
CN112773738A (zh) 一种保湿舒缓组合物，其制备方法、护肤品及应用
EP2253304B1 (fr) Composition contenant de la nifédipine pour le traitement des rides
KR20200135807A (ko) 미용적 국소 적용을 위한 건조 필름의 용도
CN107998017A (zh) 一种含有桂花提取物的祛皱、亮肤组合物及其制备方法
RU2780260C1 (ru) Средство косметического использования для кожи
CN114632045B (zh) 一种抗衰老组合物及制备方法与应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11782688

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11782688

Country of ref document: EP

Kind code of ref document: A1